

ACCORD checklist manuscript

1 **ACCORD (ACcurate COnsensus Reporting Document): A**
2 **reporting guideline for consensus methods in biomedicine**
3 **developed via a modified Delphi**

4 *Running head: ACCORD: a reporting guideline for consensus methods in biomedicine*
5 *developed via a modified Delphi*

6 William T. Gattrell,^{1*} Patricia Logullo,² Esther J. van Zuuren,³ Amy Price,⁴ Ellen L.
7 Hughes,⁵ Paul Blazey,⁶ Christopher C. Winchester,^{7,8} David Tovey,⁹ Keith Goldman,¹⁰ Amrit
8 Pali Hungin,¹¹ Niall Harrison⁵

9 ¹ Bristol Myers Squibb, Uxbridge, UK

10 ² Centre for Statistics in Medicine, University of Oxford, and EQUATOR Network UK

11 Centre, Oxford, UK

12 ³ Leiden University Medical Centre, Leiden, The Netherlands

13 ⁴ Stanford Anesthesia, Informatics and Media Lab, Stanford University School of Medicine,

14 Stanford, CA, USA

15 ⁵ OPEN Health Communications, Marlow, UK

16 ⁶ Department of Medicine, University of British Columbia, Vancouver, Canada

17 ⁷ Oxford PharmaGenesis, Oxford, UK

18 ⁸ Green Templeton College, University of Oxford, UK

19 ⁹ Journal of Clinical Epidemiology, London, UK

20 ¹⁰ Global Medical Affairs, AbbVie, North Chicago, IL, USA

21 ¹¹ Faculty of Medical Sciences, Newcastle University, Newcastle, UK

ACCORD checklist manuscript

22 * Corresponding author: William T. Gattrell

23 E-mail: william.gattrell@bms.com

24 ORCID IDs:

25 CCW: <https://orcid.org/0000-0003-3267-3990>

26 PL: <https://orcid.org/0000-0001-8708-7003>

27 PB: <https://orcid.org/0000-0002-8149-9514>

28 KG: <https://orcid.org/0000-0002-5497-8413>

29 DT: <https://orcid.org/0000-0002-8889-9246>

30 EJvZ: <https://orcid.org/0000-0002-4780-0182>

31 ELH: <https://orcid.org/0000-0003-2012-0037>

32 NH: <https://orcid.org/0000-0001-6399-6763>

33 WG: <https://orcid.org/0000-0002-9733-6330>

34 AP: <https://orcid.org/0000-0002-5200-7322>

35

36 **Abstract**

37 **Background:** In biomedical research, it is often desirable to seek consensus among
38 individuals who have differing perspectives and experience. This is important when evidence
39 is emerging, inconsistent, limited or absent. Even when research evidence is abundant,
40 clinical recommendations, policy decisions and priority-setting may still require agreement
41 from multiple, sometimes ideologically opposed parties. Despite their prominence and
42 influence on key decisions, consensus methods are often poorly reported. We aimed to
43 develop the first reporting guideline applicable to all consensus methods used in biomedical
44 research, called ACCORD (ACcurate COnsensus Reporting Document).

45 **Methods:** We followed methodology recommended by the EQUATOR Network for the
46 development of reporting guidelines: a systematic review was followed by a Delphi process
47 and meetings to finalise the ACCORD checklist. The preliminary checklist was drawn from
48 the systematic review of existing literature on the quality of reporting of consensus methods
49 and suggestions from the Steering Committee.

50 **Results:** A Delphi panel (n=72) was recruited with representation from six continents and a
51 broad range of experience, including clinical, research, policy and patient perspectives. The
52 three rounds of the Delphi process were completed by 58, 54 and 51 panellists. The
53 preliminary checklist of 56 items was refined to a final checklist of 35 items relating to the
54 article title (n=1), introduction (n=3), methods (n=21), results (n=5), discussion (n=2) and
55 other information (n=3).

56 **Conclusions:** The ACCORD checklist is the first reporting guideline applicable to all
57 consensus-based studies. It will support authors in writing accurate, detailed manuscripts,
58 thereby improving the completeness and transparency of reporting and providing readers with
59 clarity regarding the methods used to reach agreement. Furthermore, the checklist will make

ACCORD checklist manuscript

- 60 the rigour of the consensus methods used to guide the recommendations clear for readers.
- 61 Reporting consensus studies with greater clarity and transparency may enhance trust in the
- 62 recommendations made by consensus panels.

63 Introduction

64 Evidence-based medicine relies on: 1) the best available evidence; 2) patients' values,
65 preferences and knowledge; and 3) healthcare professionals' experience and expertise [1, 2].
66 When healthcare professionals need to make clinical decisions, or when recommendations or
67 guidance are needed and there is uncertainty on the best course of action, such as when
68 evidence is emergent, inconsistent, limited or absent — not least in rapidly evolving fields
69 such as pandemics [3] — the collation and dissemination of knowledge, experience and
70 expertise becomes critical. Coordinating this process may be best achieved through the use of
71 formal consensus methods [4].
72 Consensus methods (Table 1) are widely applied in healthcare. However, the specific method
73 has the potential to affect the result of a consensus exercise and shape the recommendations
74 generated.

75 **Table 1.** Examples of consensus methods in healthcare-related research.*

Study purpose	How consensus helps
Clinical practice guidelines	Translating evidence into clinical recommendations, particularly where the evidence is uncertain, and incorporating multiple perspectives; creating clinical recommendations based on experience
Diagnostic guidelines	Defining the markers, signs and symptoms or thresholds that indicate a specific condition
Disease classification	Classifying disease type or severity
Establishing research priorities	Defining and ranking priorities in the context of limited resources
Developing core outcome sets	Defining the most important and clinically significant outcomes in research
Formulating policy	Analysing and interpreting evidence, its biases and strengths, to inform policies. People gathered in consensus activities can analyse evidence together from different perspectives
Reporting guidelines	Developing guidance on what should be reported in scientific articles to enhance transparency and methodological rigour

76 **The expertise needed to contribute to the consensus process will vary depending on the*
77 *research subject, and a range of participants may be required, including but not limited to:*
78 *clinical guideline developers, clinical researchers, healthcare professionals, epidemiologists,*

ACCORD checklist manuscript

79 *ethicists, funders, journal editors, laboratory specialists, medical publication professionals,*
80 *meta-researchers, methodologists, pathologists, patients and carers/families, pharmaceutical*
81 *companies, public health specialists, policymakers, politicians, research scientists, surgeons,*
82 *systematic reviewers and technicians.*

83 Consensus obtained from a group of experts using formal methods is recognised as being
84 more reliable than individual opinions and experiences [5-7]. Consensus methods help to
85 overcome the challenges of gathering opinions from a group, such as discussions being
86 dominated by a small number of individuals, peer pressure to conform to a particular opinion
87 or the risk of group biases affecting overall decision-making [4].

88 Despite their critical role in healthcare and policy decision-making, consensus methods are
89 often poorly reported [8]. Reporting guidelines can enhance the reporting quality of research
90 [9-11], and the absence of a universal reporting guideline for studies using consensus
91 methods may contribute to their well-documented suboptimal reporting quality [8, 12-15]. A
92 recent systematic review found that the quality of reporting of consensus methods in health
93 research was deficient [8], and a methodological review found that articles that provided
94 guidance on reporting Delphi methods vary widely in their criteria and level of detail [15].

95 The Conducting and Reporting Delphi Studies (CREDES) guideline was designed to support
96 the conduct and reporting of Delphi studies, with a focus on palliative care [16]. The 23-item
97 AGREE-II instrument, which is widely used for reporting clinical practice guidelines,
98 includes only one item ('Formulation of Recommendations') related to the method used to
99 obtain consensus [17].

100 Therefore, a comprehensive guideline is needed to report the numerous methods available to
101 assess and/or guide consensus in medical research. The ACcurate COnsensus Reporting
102 Document (ACCORD) reporting guideline project was initiated to fulfil this need. We

ACCORD checklist manuscript

103 followed EQUATOR Network–recommended best practices for reporting guideline
104 development, which included a systematic review and consensus exercise. Our aim was to
105 develop a new tool, applicable worldwide, that will facilitate the rigorous and transparent
106 reporting of all types of consensus methods across the spectrum of health research [18]. A
107 comprehensive reporting guideline will enable readers to understand the consensus methods
108 used to develop recommendations and will, we hope, ultimately improve patient outcomes.

109

110

111 **Methods**

112 **Scope of ACCORD**

113 ACCORD is a meta-research project to develop a reporting guideline for consensus methods
114 used in health-related activities or research (Table 2) [18]. The guideline was designed to be
115 applicable to simple and less structured methods (such as consensus meetings), more
116 systematic methods (such as nominal group technique or Delphi) or any combination of
117 methods utilised to achieve consensus. In addition, although ACCORD has been structured to
118 help reporting a scientific manuscript (with the traditional article sections such as
119 introduction, methods, results, and discussion), the checklist items can assist authors in
120 writing other types of text describing consensus activities.

121 **Table 2.** A selection of common consensus methods used in health-related activities or
122 research.

Method	Characteristics
Delphi [13, 19]	<ul style="list-style-type: none">• Anonymity• Iteration over multiple rounds of voting• Feedback after each round
Nominal group technique [20]	A face-to-face group interaction comprising four stages: <ul style="list-style-type: none">• Solo idea generation• Round-robin feedback of ideas• Clarification of ideas through discussion• Voting to prioritise or rank ideas
RAND/UCLA appropriateness method (RAM) [21]	A method developed to combine the best available scientific evidence with the collective judgement of experts to yield a statement regarding, for example, the appropriateness of performing

ACCORD checklist manuscript

	a procedure. Stages include: <ul style="list-style-type: none">• Literature review• Development of statements• Expert scoring of statements
Consensus meetings [22]	Simple meetings with discussion to reach consensus, including voting in structured or more informal formats

123

124 ACCORD is a reporting guideline which provides a checklist of items that we recommend
125 are included in any scientific publication in healthcare reporting the results of a consensus
126 exercise. However, it is not a methodological guideline. It is not intended to provide guidance
127 on how researchers and specialists should design their consensus activities, and it makes no
128 judgement on which method is most appropriate in a particular context. Furthermore,
129 ACCORD is not intended to be used for reporting research in fields outside health, such as
130 social sciences, economics or marketing.

131

132 **Study design, setting and ethics**

133 The ACCORD project was registered prospectively on 20 January 2022 on the Open Science
134 Framework [23] and the EQUATOR Network website [24] and received ethics approval from
135 the Central University Research Ethics Committee at the University of Oxford (Reference
136 number: R81767/RE001). The ACCORD protocol has been previously published [18] and
137 followed the EQUATOR Network recommendations for developing a reporting guideline
138 [25, 26], starting with a systematic review of the literature [8], followed by a Delphi process
139 that was modified by basing the preliminary list for voting on a systematic review rather than
140 initial ideas or statements from the panellists themselves. In addition, the ACCORD Steering

ACCORD checklist manuscript

141 Committee made final decisions on item inclusion and refined the checklist wording as
142 described below.

143

144 **ACCORD Steering Committee**

145 WG and NH founded the ACCORD project, seeking endorsement from the International
146 Society of Medical Publication Professionals (ISMPP) in April 2021. ISMPP provided
147 practical support and guidance on the overall process at project outset but was not involved in
148 checklist development. The ACCORD Steering Committee, established over the following
149 months, was multidisciplinary in nature and comprised researchers from different countries
150 and settings. Steering Committee recruitment was iterative, with new members invited as
151 needs were identified by the founders and existing committee, to ensure inclusion of the
152 desired range of expertise or experience. Potential members were identified via ISMPP,
153 literature research, professional connections and network recommendations. When the
154 protocol was submitted for publication, the Steering Committee had 11 members (WG, PL,
155 EvZ, AP, EH, CW, DT, KG, AH, NH and Robert Matheis [RM] from ISMPP). Bernd Arents
156 joined the Steering Committee in July 2021 but left in December of that year, as did RM in
157 August 2022, both citing an excess of commitments as their reason for stepping down. AP
158 provided methodology and lay perspectives throughout the study design and conduct, and in
159 the development and writing up of the materials; she is a research methodologist and a head
160 and spinal trauma survivor. Patient partners were invited as Delphi panellists. Paul Blazey
161 joined the Steering Committee in September 2022 as a methodologist to support the
162 execution of the ACCORD Delphi process and provide additional expertise on consensus
163 methods.

ACCORD checklist manuscript

164 The final Steering Committee responsible for the Delphi process and development of the
165 checklist had members from multiple countries and included clinician practitioners,
166 methodologists, medical publication professionals, journal editors, a representative of the
167 EQUATOR Network and a representative of the public (Supporting Information [SI] file 1).

168

169 **Protocol development**

170 The ACCORD protocol was developed by the Steering Committee before the literature
171 searches or Delphi rounds were commenced and has been published previously [18]. An
172 overview of the methods used, together with some amendments made to the protocol during
173 the development of ACCORD in response to new insights, is provided below.

174

175 **Systematic review and development of preliminary checklist**

176 A subgroup of the Steering Committee conducted a systematic review with the dual purpose
177 of identifying existing evidence on the quality of reporting of consensus methods and
178 generating the preliminary draft checklist of items which should be reported [8]. The
179 systematic review identified 18 studies which addressed the quality of reporting of consensus
180 methods, with 14 studies focussed on Delphi only and four studies including Delphi and other
181 methods [8]. A list of deficiencies in consensus reporting was compiled based on the findings
182 of the systematic review. Items in the preliminary checklist were subsequently derived from
183 the systematic review both from the data extraction list (n=30) [8] and from other information
184 that was relevant for reporting consensus methods (n=26) [8].

185 Next, the Steering Committee voted on whether the preliminary checklist items (n=56)
186 should be included in the Delphi via two anonymous online surveys conducted using

ACCORD checklist manuscript

187 Microsoft Forms (See SI2). There were five voting options: ‘Strongly disagree’, ‘Disagree’,
188 ‘Agree’, ‘Strongly agree’ and ‘Abstain/Unable to answer’. NH processed the results in Excel
189 and WG provided feedback and therefore neither voted. Items that received sufficient support
190 (i.e., >80% of respondents voted “Agree”/“Strongly agree”) were included in the Delphi
191 while the rest were discussed by the Steering Committee for potential inclusion or removal.
192 During the first survey, Steering Committee members could propose additional items based
193 on their knowledge and expertise. These new items were voted on in the second Steering
194 Committee survey. Upon completion of this process, the Steering Committee approved and
195 updated the preliminary draft checklist, which was then prepared for voting on by the Delphi
196 panel. Items were clustered or separated as necessary for clarity.

197

198 **Delphi panel composition**

199 Using an anonymous survey (9–13 June 2022), the Steering Committee voted on the desired
200 profile of Delphi panellists for the ACCORD project. There was unanimous agreement that
201 geographic representation was important, and the aim was to recruit from all continents
202 (thereby covering both Northern and Southern hemispheres) and include participants from
203 low-, middle- and high-income countries to account for potential differences in cultural and
204 ideological ways of reaching agreement. The aim was to include a broad range of
205 participants: clinicians, researchers experienced in the use of consensus methods and in
206 clinical practice guideline development, patient advocates, journal editors, publication
207 professionals and publishers, regulatory specialists, public health policymakers and
208 pharmaceutical company representatives. The target panel size (approximately 40 panellists)
209 was guided by the desired representation and to ensure an acceptable number of responses

ACCORD checklist manuscript

210 (20, assuming a participation rate of 50%) in the event of withdrawals or partial completion
211 of review.

212

213 **Delphi panel recruitment**

214 Potential participants for the Delphi panel were identified in several ways: from the author
215 lists of publications included in the systematic review, from invitations circulated via an
216 EQUATOR Network newsletter (October 2021) [27] and at the ISMPP EU meeting in
217 January 2022, and by contacting groups potentially impacted by ACCORD (e.g., the UK
218 National Institute for Health and Care Excellence [NICE]). Individuals were also invited to
219 take part through the ACCORD protocol publication [18], and the members of the Steering
220 Committee contacted individuals in their networks to fill gaps in geographical or professional
221 representation. To minimise potential bias, none of the Steering Committee participated in the
222 Delphi panel.

223 Invitations were issued to candidate panellists who satisfied the inclusion criteria. While
224 participants were not generally asked to suggest other panel members, in some cases, invitees
225 proposed a colleague to replace them on the panel. Only the Steering Committee members
226 responsible for administering the Delphi had access to the full list of ACCORD Delphi panel
227 members. Panellists were invited by email, and reminder emails were sent to those who did
228 not respond. Out of the 133 panellists invited, 72 agreed to participate. No panellists or
229 Steering Committee members were reimbursed or remunerated for taking part in the
230 ACCORD project.

231

232 **Planned Delphi process**

233 The Delphi method was chosen to validate the checklist, in line with recommendations for
234 developing reporting guidelines [25]. A three-round Delphi was planned to allow for
235 iteration, with the option to include additional rounds if necessary. Panellists who agreed to
236 take part received an information pack containing an introductory letter, a plain language
237 summary, an informed consent statement, links to the published protocol and systematic
238 review, and the items excluded by the Steering Committee (See SI3). Survey materials were
239 developed by PL and PB in English and piloted by WG and NH. Editorial and formatting
240 changes were made following the pilot stage to optimise the ease of use of the survey. In an
241 amendment to the protocol, the order of candidate items was not randomised within each
242 manuscript section. The Jisc Online Survey platform (Jisc Services Ltd., Bristol, UK) was
243 used to administer all Delphi surveys, ensuring anonymity through automatic coding of
244 participants. Panellists were sent reminders to complete the survey via the survey platform,
245 and one email reminder was sent to panellists the day before the deadline for each round.

246 The Delphi voting was modified to offer five voting options: ‘Strongly disagree’, ‘Disagree’,
247 ‘Neither agree nor disagree’, ‘Agree’, and ‘Strongly agree’. Votes of ‘Neither agree nor
248 disagree’ were included in the denominator. The consensus threshold was defined *a priori* as
249 $\geq 80\%$ of a minimum of 20 respondents voting ‘Agree’ or ‘Strongly agree’. Reaching the
250 consensus threshold was not a stopping criterion. For inclusion in the final checklist, each
251 item was required to achieve the consensus criteria following at least two rounds of voting.
252 This ensured that all items had the opportunity for iteration between rounds (a central tenet of
253 the Delphi method) [19] and enabled panellists to reconsider their voting position in light of
254 feedback from the previous round.

ACCORD checklist manuscript

255 In Round 1, panellists had the opportunity, anonymously, to suggest new items to be voted on
256 in subsequent rounds. Panellists were also able to provide anonymous free-text comments in
257 each round to add rationale for their chosen vote or suggest alterations to the item text. After
258 each voting round, the comments were evaluated and integrated by WG, PL, PB and NH and
259 validated by the Steering Committee. If necessary, semantic changes were made to items to
260 improve clarity and concision.

261 Feedback given to participants between rounds included the anonymised total votes and the
262 percentage in each category (see example in Figure 1) to allow panellists to assess their
263 position in comparison with the rest of the group, as well as the relevant free-text comments
264 on each item. Items that did not achieve consensus in Rounds 1 and 2 were revised or
265 excluded based on the feedback received from the panellists. Items that were materially
266 altered (to change their original meaning) were considered a new item. All wording changes
267 were recorded. Panellists received a table highlighting wording changes as part of the
268 feedback process so that they could see modifications to checklist items (for example
269 feedback documents, see SI4).

270 **Figure 1.** Example of feedback provided to panellists. Modifications to the text are
271 underlined

Round 1 statement

M10. Describe the role of any public, lay or patient participants. Detail the stage(s) at which they were involved, and their roles and contributions.

Summary and comments from Round 1

ACCORD checklist manuscript

21.1 Do you agree with the inclusion of this item in the ACCORD checklist?

Response	Count	Percentage
Strongly disagree	0	0%
Disagree	5	8.8%
Neither agree nor disagree	2	3.5%
Agree	22	38.6%
Strongly agree	28	49.1%

Multi answer: Percentage of respondents who selected each answer option (e.g. 100% would represent that all this question's respondents chose that option)

I disagree with the wording "M10. Describe the role of any public, lay, or patient participants." Suggest deleting "lay" and replace with: "M10. Describe the role of public and patient partners."

I think rephrase to 'Explicitly detail the stage(s) at which they were involved, and their roles and contributions' - it is really important that the detail is provided, this is key to understanding how stakeholder driven the consensus is

M10 no cohort should be singled out. Any participation should be seen as equal by the expertise they bring to the process.

It is important to emphasise the patient community voice

M 10 Describe the role of any public, lay, or patient participants. Suggest for ALL participants as depending on your question the MDs might be the minority

Re 21 and 22. Has the tone and manner of the questions been written to match that of the respondents? (lay language for lay, for example) Have the questions been checked and vetted by the Plain English Society

Lay panel members, with expertise anchored in their lived experience, should be accorded as similar a status with professional experts as possible, and language in the checklist should reflect that, Also, should be made clearer that investigators should ensure they describe involvement of lay members of steering committee in earlier methods items

Modification made between Round 1 and Round 2

Describe the role(s) of any public, lay or patient participants in the different stages of the study. If these groups did not participate, justify why this was the case.

ACCORD checklist manuscript

273 Items reaching consensus over two rounds were removed from the Delphi for inclusion in the
274 checklist. Items achieving agreement in Round 1 which then fell into disagreement in Round
275 2 were considered to have ‘unstable’ agreement. These unstable items were revised based on
276 qualitative feedback from the panel and were included for re-voting in Round 3.

277 **Steering Committee checklist finalisation process**

278 Consistent with the protocol [18], following completion of the Delphi process, the Steering
279 Committee was convened for a series of three two-hour virtual workshops (7, 14 and 16
280 March 2023) to make decisions and finalise the checklist. For each item, WG, PL, PB and
281 NH presented a summary of voting, comments received and a recommended approach. The
282 possible recommended approaches are shown in Table 3.

283 **Table 3.** Recommended approaches to approved and rejected items used during the checklist
284 finalisation workshops.

Approved items	Rejected items
<ul style="list-style-type: none">• Keep item as approved (default)• Keep item with wording changes based on panellist comments (requires unanimous Steering Committee approval)• Keep item, but combine with another item or help text where contents appear to relate strongly to one another (requires unanimous Steering Committee approval)	<ul style="list-style-type: none">• Confirm item is rejected (default)• Restore item: Requirements to restore:<ol style="list-style-type: none">1. item already close to acceptance (70%–80% agreement);2. positive comments with supporting rationale from panellists; and3. unanimous Steering Committee approval

285

ACCORD checklist manuscript

286 All recommendations were followed by an explanation of why WG, PL, PB or NH felt this
287 would be the most appropriate action and a discussion between Steering Committee members
288 in which the suggested action could be challenged and changed.

289 Grammatical changes were also considered at this stage but only where they did not change
290 the meaning of an approved item. Following review of all items, the order of the checklist
291 items was evaluated by WG, PL, PB and NH.

292 **Standardised terminology**

293 After the consensus meetings, NH updated and standardised the terminology according to the
294 type of information requested in the item to ensure consistency between items, and this was
295 approved by the Steering Committee. This standardisation of terminology incorporated rules
296 established for the use of terms common in reporting guidelines, as shown in Table 4, such as
297 the difference between using “state” or “describe”. All but two items (R5 and O1) contain a
298 verb from Table 4.

299

300 **Table 4.** Criteria for the standardisation of terms used to guide reporting in ACCORD.

Verb	Type of information
Describe	Processes (e.g., recruitment) or broad topics (e.g., areas of expertise)
State	Factual information, e.g., conflicts of interest
Explain	Methodological choices that may not be immediately transparent, e.g., criteria for panellist inclusion
Report	Reserved for (most) results items
Discuss	Reserved for discussion items

301 **Results**

ACCORD checklist manuscript

302 **Delphi panel demographics**

303 The Delphi panel included a diverse group of panellists, representing a wide range of
 304 geographical areas and professions (Table 5). Of the 72 participants who indicated their
 305 willingness to participate in the Delphi panel, 58 (81%) completed Round 1 and were invited
 306 to Round 2. Fifty-four participants completed Round 2 and were invited to Round 3, which
 307 was completed by 51 participants.

308 **Table 5.** Self-identified demographics of the Delphi panellists, per voting round.

Characteristic	Round 1 (n=58) 21 October–4 November 2022	Round 2 (n=54) 21 December 2022–16 January 2023	Round 3 (n=51) 10–27 Feb 2023
Gender, n (%)			
Female	31 (53.4)	28 (51.9)	28 (54.9)
Male	27 (46.6)	25 (46.3)	22 (43.1)
Non-binary	0	1 (1.9)	0
Prefer not to say	0	0	1 (2.0)
Geographic location of current primary residence and work, n (%)			
Africa	3 (5.2)	3 (5.6)	2 (3.9)
Asia	4 (6.9)	4 (7.4)	4 (7.8)
Europe	31 (53.4)	28 (51.9)	26 (51.0)
North America	16 (27.6)	15 (27.8)	15 (29.4)
Oceania	1 (1.7)	1 (1.9)	1 (2.0)
South America	3 (5.2)	3 (5.6)	3 (5.9)
Background*, n (%)			
Clinician	16 (27.6)	14 (25.9)	13 (25.5)
Journal editor	8 (13.8)	6 (11.1)	8 (15.7)
Patient partner [†]	6 (10.3)	6 (11.1)	5 (9.8)
Policymaker	3 (5.2)	3 (5.6)	4 (7.8)
Publications professional	17 (29.3)	17 (31.5)	15 (29.4)
Researcher	29 (50.0)	29 (53.7)	24 (47.1)
Other [‡]	11 (19)	6 (11.1)	8 (15.7)

309 *Panellists could select more than one option.

310 [†]In Rounds 2 and 3, this category was changed to: Patient, Patient Partner, Family Member or
 311 Carer.

312

313 [‡]Other occupation categories included:

314 In Round 1: Patient & Research Community: Pharmaceutical Physician; Research Funder;

ACCORD checklist manuscript

315 Academician (Professor); Guideline Developer; Medical Communications Services; Data
316 manager; Research in Medical Education; Healthcare Consultant; Patient Advocacy Leader;
317 Physician; Health and Care Guideline Developer.
318 In Round 2: Data Manager; Medical Education Research and Clinician; Guideline Developer;
319 Administrator; Professor.
320 In Round 3: Data Manager; Consensus Development Facilitator; Professor; Patient
321 Organisation; Guideline Developer.

322


323 **Delphi results**

324 The updated preliminary draft checklist presented to the Delphi panel for voting contained 41
325 items. The changes in the number of checklist items over the Delphi voting rounds are
326 illustrated in Figure 2. After Round 1, seven new items were added, and one item was lost by
327 combining with another item, resulting in 47 items being included in Round 2. Only items
328 that were unstable (n=4) or were modified sufficiently to be considered new (n=6) were voted
329 on in Round 3. After Round 2, 33 items achieved consensus, and a further three items
330 achieved consensus after all three rounds of voting. Therefore, at the end of the Delphi
331 process, consensus was reached on 36 items. The results of the Delphi process, showing the
332 iteration of items and level of agreement at each round, are summarised in SI5.

333

ACCORD checklist manuscript

334 **Figure 2.** A flow diagram to show the development of checklist items.



335

336 *Potential items from relevant information beyond the predefined data extraction form

337 [8].

338 †New item (T1) proposed at checklist review meeting.

339

340 **Finalisation by Steering Committee**

341 One item rejected by the Delphi panel was restored to the checklist (M10, becoming item

342 M5), and three highly approved (>90%) items were modified by combining with other items

343 during the Steering Committee finalisation workshops.

344 **Restored item (Delphi M10 > Final M5)**

345 Delphi item M10 (patient and public involvement) failed to achieve stable consensus during

346 the voting process (Round 1, 87.5%; Round 2, 73.1%; Round 3, 76%). The comments from

347 the panel led the Steering Committee to conclude that panellists had not reached agreement

348 on reporting patient and public involvement due to the item being essential in some—but not

ACCORD checklist manuscript

349 all—consensus processes (“*Depends on the topic of Delphi consensus, should be optional*”;
350 “*For me this rests on the topic of the exercise*”), and because of disagreements about
351 preferred terminology (“*The difference between lay and patient and public partners is*
352 *potentially confusing*”; “*DO NOT change ‘participants’ to ‘partners’*”). However, the
353 Steering Committee identified many situations where the inclusion of patients would be
354 considered essential. Priority-setting and core outcome identification are just two areas where
355 patient participation in consensus exercises is becoming standard [28-30]. Based on
356 unanimous agreement (11/11), the Steering Committee decided to reinstate M10 as reporting
357 item M5, while taking into account the most consistent comments regarding wording
358 (notably, that “lay” should not be used).

359 **Items with high level of agreement that were modified**

360 Three original items, R3, R6 and R7, overlapped by all covering aspects of which data were
361 reported from the Delphi voting rounds. During the checklist finalisation workshops, the
362 Steering Committee discussed these three items and combined them to create two final items,
363 R3 (quantitative data) and R4 (qualitative data). In addition, the Steering Committee noted an
364 overlap between original items M22 and R8 related to modifications made to items or topics
365 during the consensus process. These two items were combined to create the final item R5.
366 Finally, M13 was revised to remove a conceptual overlap with M12 and to use clearer
367 language.

368 **Final checklist**

369 The final ACCORD checklist comprised 35 items that were identified as essential to ensure
370 clear and transparent reporting of consensus studies. The finalised ACCORD checklist is
371 presented in Table 6.

372 **Table 6.** The final ACCORD checklist for the reporting of consensus methods.

Item number	Manuscript section	Item wording	Help text
T1	Title	Identify the article as reporting a consensus exercise and state the consensus methods used in the title.	For example, Delphi or nominal group technique.
I1	Introduction	Explain why a consensus exercise was chosen over other approaches.	n/a
I2	Introduction	State the aim of the consensus exercise, including its intended audience and geographical scope (national, regional, global).	n/a
I3	Introduction	If the consensus exercise is an update of an existing document, state why an update is needed, and provide the citation for the original document.	n/a
M1	Methods > Registration	If the study or study protocol was prospectively registered, state the registration platform and provide a link. If the exercise was not registered, this should be stated.	Recommended to include the date of registration.
M2	Methods > Selection of	Describe the role(s) and areas of expertise or	For example, whether the project was led by a chair,

	SC and/or panellists	experience of those directing the consensus exercise.	co-chairs or a steering committee, and, if so, how they were chosen. List their names if appropriate, and whether there were any subgroups for individual steps in the process.
M3	Methods > Selection of SC and/or panellists	Explain the criteria for panellist inclusion and the rationale for panellist numbers. State who was responsible for panellist selection.	n/a
M4	Methods > Selection of SC and/or panellists	Describe the recruitment process (how panellists were invited to participate).	Include communication/advertisement method(s) and locations, numbers of invitations sent, and whether there was centralised oversight of invitations or if panellists were asked/allowed to suggest other members of the panel.
M5	Methods > Selection of SC and/or panellists	Describe the role of any members of the public, patients or carers in the different steps of the study.	n/a
M6	Methods > Preparatory research	Describe how information was obtained prior to generating items or other materials used during the consensus exercise.	This might include a literature review, interviews, surveys, or another process.

ACCORD checklist manuscript

M7	Methods > Preparatory research	Describe any systematic literature search in detail, including the search strategy and dates of search or the citation if published already.	Provide the details suggested by the reporting guideline PRISMA and the related PRISMA-Search extension.
M8	Methods > Preparatory research	Describe how any existing scientific evidence was summarised and if this evidence was provided to the panellists.	n/a
M9	Methods > Assessing consensus	Describe the methods used and steps taken to gather panellist input and reach consensus (for example, Delphi, RAND-UCLA, nominal group technique).	If modifications were made to the method in its original form, provide a detailed explanation of how the method was adjusted and why this was necessary for the purpose of your consensus-based study.
M10	Methods > Assessing consensus	Describe how each question or statement was presented and the response options. State whether panellists were able to or required to explain their responses, and whether they could propose new items.	Where possible, present the questionnaire or list of statements as supplementary material.
M11	Methods > Assessing consensus	State the objective of each consensus step.	A step could be a consensus meeting, a discussion or interview session, or a Delphi round.

M12	Methods > Assessing consensus	State the definition of consensus (for example, number, percentage, or categorical rating, such as ‘agree’ or ‘strongly agree’) and explain the rationale for that definition.	n/a
M13	Methods > Assessing consensus	State whether items that met the prespecified definition of consensus were included in any subsequent voting rounds.	n/a
M14	Methods > Assessing consensus	For each step, describe how responses were collected, and whether responses were collected in a group setting or individually.	n/a
M15	Methods > Assessing consensus	Describe how responses were processed and/or synthesised.	Include qualitative analyses of free-text responses (for example, thematic, content or cluster analysis) and/or quantitative analytical methods, if used.
M16	Methods > Assessing consensus	Describe any piloting of the study materials and/or survey instruments.	Include how many individuals piloted the study materials, the rationale for the selection of those individuals, any changes made as a result and whether their responses were used in the calculation of the final

			consensus. If no pilot was conducted, this should be stated.
M17	Methods > Assessing consensus	If applicable, describe how feedback was provided to panellists at the end of each consensus step or meeting.	State whether feedback was quantitative (for example, approval rates per topic/item) and/or qualitative (for example, comments, or lists of approved items), and whether it was anonymised.
M18	Methods > Assessing consensus	State whether anonymity was planned in the study design. Explain where and to whom it was applied and what methods were used to guarantee anonymity.	n/a
M19	Methods > Assessing consensus	State if the steering committee was involved in the decisions made by the consensus panel.	For example, whether the steering committee or those managing consensus also had voting rights.
M20	Methods > Participation	Describe any incentives used to encourage responses or participation in the consensus process.	For example, were invitations to participate reiterated, or were participants reimbursed for their time.
M21	Methods > Participation	Describe any adaptations to make the surveys/meetings more accessible.	For example, the languages in which the surveys/meetings were conducted and whether translations or plain language summaries were

			available.
R1	Results	<p>State when the consensus exercise was conducted.</p> <p>List the date of initiation and the time taken to complete each consensus step, analysis, and any extensions or delays in the analysis.</p>	n/a
R2	Results	<p>Explain any deviations from the study protocol, and why these were necessary.</p>	<p>For example, addition of panel members during the exercise, number of consensus steps, stopping criteria; report the step(s) in which this occurred.</p>
R3	Results	<p>For each step, report quantitative (number of panellists, response rate) and qualitative (relevant socio-demographics) data to describe the participating panellists.</p>	n/a
R4	Results	<p>Report the final outcome of the consensus process as qualitative (for example, aggregated themes from comments) and/or quantitative (for example, summary statistics, score means, medians and/or ranges) data.</p>	n/a

R5	Results	List any items or topics that were modified or removed during the consensus process. Include why and when in the process they were modified or removed.	n/a
<u>D1</u>	Discussion	Discuss the methodological strengths and limitations of the consensus exercise.	Include factors that may have impacted the decisions (for example, response rates, representativeness of the panel, potential for feedback during consensus to bias responses, potential impact of any non-anonymised interactions).
D2	Discussion	Discuss whether the recommendations are consistent with any pre-existing literature and, if not, propose reasons why this process may have arrived at alternative conclusions.	n/a
O1	Other information	List any endorsing organisations involved and their role.	n/a
O2	Other information	State any potential conflicts of interests, including among those directing the consensus study and	n/a

		panellists. Describe how conflicts of interest were managed.	
O3	Other information	State any funding received and the role of the funder.	Specify, for example, any funder involvement in the study concept/design, participation in the steering committee, conducting the consensus process, funding of any medical writing support. This could be disclosed in the methods or in the relevant transparency section of the manuscript. Where a funder did not play a role in the process or influence the decisions reached, this should be specified.

373 n/a, not applicable.

374 **Discussion**

375 The ACCORD checklist has been developed using a robust and systematic approach, with
376 input from participants with a variety of areas of expertise, and it is now available for any
377 health researcher to use to report studies that use consensus methods. The process of
378 developing ACCORD itself used consensus methods which are reported here according to the
379 checklist developed.

380

381 **Why ACCORD was needed**

382 The need for optimal reporting of consensus methods has been documented for decades [8,
383 14]. Generic problems identified include inconsistency and lack of transparency in reporting,
384 as well as more specific criticisms such as lack of detail regarding how participants or
385 steering committee members were selected, missing panellist background information, no
386 definition of consensus, missing response rates after each consensus round, no description of
387 level of anonymity or how anonymity was maintained, and a lack of clarity over what
388 feedback was provided between rounds [8]. The absence of a reporting guideline that
389 encompasses the range of consensus methods may contribute to poor reporting quality [13],
390 and this prompted the development of the ACCORD checklist.

391 Two EQUATOR-listed checklists are available that include consensus or support clinical
392 practice guideline reporting, which often includes a consensus exercise. CREDES [16] is a
393 method- and speciality-specific guideline aimed at supporting the conduct and reporting of
394 Delphi studies in palliative care. AGREE-II is focused on appropriate reporting and
395 evaluation of clinical practice guidelines; it has only one item, 'Formulation of
396 Recommendations', relating to the method used to obtain consensus [17]. ACCORD

397 addresses the breadth of methods used to attain consensus (including the Delphi method) and
398 should be complementary to AGREE-II where a clinical practice guideline also includes a
399 formal consensus development process. Another reporting guideline currently under
400 development, DELPHISTAR [15], is Delphi specific and covers medical and social sciences.
401 ACCORD extends beyond Delphi methods and encompasses a wide range of consensus
402 methods in various health-related fields.

403 Although familiarity with ACCORD is likely to be useful to ensure relevant elements are
404 considered when designing a consensus study, it is a reporting guideline and not a mandate
405 for study conduct. The methodological background to the items and published examples of
406 what we consider to be good reporting will be discussed in the ACCORD Explanation and
407 Elaboration document (manuscript in preparation).

408

409 **Strengths and limitations**

410 ACCORD was conducted through an open, collaborative process with a predefined,
411 published protocol [18]. It started with a systematic review [8] using robust methods of
412 searching, screening and extraction, which led to the identification of common gaps in
413 reporting consensus methods. Only 18 studies were eligible for inclusion in the systematic
414 review, and data extraction generated 30 potential checklist items. An additional 26 items
415 were identified that were not covered by the data extraction list. Following this thorough
416 process, these 56 potential items were supplemented by a further 9 proposed by the Steering
417 Committee, with an additional 7 proposed by Delphi panellists.

418 The ACCORD checklist involved input from participants with a wide range of expertise,
419 including methodologists, patient advocates, healthcare professionals, journal editors,
420 publication professionals, and representatives from the pharmaceutical industry and bodies

421 such as NICE and the Scottish Intercollegiate Guidelines Network. With a few exceptions
422 reported here, their recommendations were fully adopted and integrated into the final
423 checklist. ACCORD was developed to assist everyone involved in consensus-based activities
424 or research. It will assure participants that methods will be accurately reported; guide authors
425 when writing up a publication; help journal editors and peer reviewers when assessing a
426 manuscript for publication; and enhance trust in the recommendations made by consensus
427 panels. Our hope is that ACCORD will ultimately benefit patients by improving the
428 transparency and robustness of consensus studies in healthcare.

429 A limitation of the ACCORD initiative is that the panel was largely drawn from Europe and
430 North America. Although invitations were sent to potential panellists in South America, Asia,
431 Africa and Oceania, few responses were obtained, leading to limited participation from these
432 continents. In future updates or extensions, the project would benefit from recruiting
433 panellists with experience in consensus from other regions and countries with different
434 cultures and health systems.

435 Members of the ACCORD Steering Committee did not vote in the Delphi surveys. In our
436 process, the virtual workshops held to finalise the ACCORD checklist did not include the
437 Delphi panel. This might be seen as a limitation by some, especially those involved in
438 reporting guidelines development, as a consensus meeting including some expert members of
439 the Delphi panel is usually conducted according to the guidance issued by the EQUATOR
440 Network [25]. However, our process held the Steering Committee and Delphi panel separate:
441 the Steering Committee did not participate in the Delphi panel, and the Delphi panellists did
442 not participate in the final consensus discussions. One item was included in the checklist
443 without full approval of the Delphi panel (see results and commentary for item M5).

444 Stability of agreement indicates when consensus is present among a group. There are several
445 methods to assess for stability, but ACCORD adhered to a simple definition of achieving the
446 *a priori* agreed threshold for agreement over a minimum of two voting rounds [31].

447 Another limitation which consensus and survey specialists may note is that the items in our
448 Delphi survey were not presented to panellists in a random order. Since ACCORD was
449 proposing content items for the sections of a scientific manuscript (title, introduction,
450 methods, results and discussion), we preferred to present items in these sections in the order
451 that they usually appear to enhance comprehension and avoid confusion. This is something
452 that may affect all reporting guidelines development. In fact, several panellists provided
453 feedback on how to order the items.

454

455 **The implementation of the ACCORD reporting guideline**

456 Many reporting guidelines are published without initiatives to facilitate implementation. Only
457 15.7% of guidelines on the EQUATOR Network website mentioned an implementation plan
458 [26]. Piloting is planned to inform an Explanation & Elaboration document, and a full
459 implementation plan for ACCORD is being developed.

460

461 **The future of ACCORD**

462 Robust reporting is particularly important for studies using consensus methods given that so
463 many methods exist and researchers frequently make modifications to ‘standard’ methods.
464 We anticipate that updates of the ACCORD checklist will be necessary, as technology and
465 consensus methods continue to evolve.

466 Besides updates, ACCORD could have extensions developed in areas such as non-clinical
467 biomedical studies, health economics, or health informatics and artificial intelligence, and
468 even beyond healthcare, with input from appropriate experts. The Steering Committee
469 welcomes feedback and interest from other researchers in these areas.

470

471 **Conclusion**

472 The ACCORD reporting guideline provides the scientific community with an important tool
473 to improve the completeness and transparency of reporting of studies that use consensus
474 methods. The ACCORD checklist supports authors in writing manuscripts with sufficient
475 information to enable readers to understand the study's methods, the study's results, and the
476 interpretation of those results so that they can draw their own conclusions about the
477 robustness and credibility of the recommendations.

478 **Author Contributions**

479 William T. Gattrell: conceptualization, methodology, formal analysis, data curation, original

480 draft preparation, reviewing, editing

481 Patricia Logullo: conceptualization, methodology, formal analysis, data curation, original

482 draft preparation, reviewing, editing

483 Esther J. van Zuuren: conceptualization, methodology, reviewing, editing

484 Amy Price: conceptualization, methodology, reviewing

485 Ellen L. Hughes: conceptualization, methodology, reviewing

486 Paul Blazey: methodology, formal analysis, data curation, original draft preparation,

487 reviewing, editing

488 Christopher C. Winchester: conceptualization, methodology, reviewing, editing

489 David Tovey: conceptualization, methodology, reviewing, editing

490 Keith Goldman: conceptualization, methodology, reviewing, editing

491 Amrit Pali Hungin: conceptualization, methodology, reviewing

492 Niall Harrison: conceptualization, methodology, formal analysis, data curation, reviewing,

493 editing

494 All authors contributed to the development of the manuscript, and reviewed, commented and

495 approved the final version for publication.

496

497 **Acknowledgements**

498 The authors would like to thank all the Delphi panellists for their vital contribution to the
499 project, including Anirudha Agnihotry, DDS; Brian S. Alper, MD, MSPH, FAAFP, FAMIA;
500 Julian Amorin-Montes; Thierry Auperin, PhD; Slavka Baronikova; Franco Bazzoli; Marnie
501 Brennan; Melissa Brouwers, PhD; Klara Brunnhuber; Teresa M. Chan; Martine Docking;
502 Jenny Fanstone; Ivan D. Florez; Suzanne B. Gangi; Sean Grant; Susan Humphrey-Murto;
503 Alexandra Frances Kavaney; Rachel E. Kettle, PhD; Samson G. Khachatryan; Karim Khan,
504 MD, PhD; Margarita Lens, MSci; Elizabeth Loder, MD, MPH; Aubrey Malden; Lidwine B.
505 Mokkink; Ronald Munatsi; Prof. Dr. Marlen Niederberger; Mina Patel, PhD; William R.
506 Phillips, MD, MPH; Kris Pierce; Sheuli Porkess; Weini Qiu; Linda Romagnano, PhD;
507 Maurizio Scarpa, MD, PhD; Dan Shanahan; Paul Sinclair; Professor Ripudaman Singh; Dr
508 Curtis Sonny; Ms Ailsa Stein; Carey M Suehs; Bob Stevens; Dr Chit Su Tinn; Vasilii
509 Vlassov; KP Vorobyov, MD. Project management support was provided by Mark Rolfe,
510 Helen Bremner, Amie Hedges and Mehraj Ahmed from Oxford PharmaGenesis. The authors
511 would like to thank the support provided by ISMPP, in particular the input provided by the
512 current President, Robert Matheis, at the outset of the project. Jan Schoones (Leiden
513 University Medical Centre) assisted in development of the search strategy. Laura Harrington,
514 PhD, an employee of Ogilvy Health, provided medical writing support.

515 **Disclosures**

516 PL is a member of the UK EQUATOR Centre, based in the University of Oxford;
517 EQUATOR promotes the use of reporting guidelines, many of which are developed using
518 consensus methods, and she is personally involved in the development of other reporting
519 guidelines. WG is an employee of Bristol Myers Squibb. KG is an employee of AbbVie.
520 APH, in the last five years, worked with Reckitt Benckiser for the development of the
521 definitions and management of gastro-oesophageal reflux disease. CCW is an employee,

522 Director, and shareholder of Oxford PharmaGenesis Ltd., a Director of Oxford Health Policy
523 Forum CIC, a Trustee of the Friends of the National Library of Medicine, and an Associate
524 Fellow of Green Templeton College, University of Oxford. NH and EH are employees of
525 OPEN Health Communications. DT is co–editor-in-chief of the *Journal of Clinical*
526 *Epidemiology* and chairs the Scientific Advisory Committee for the Centre for Biomedical
527 Transparency. AP, PB and EJvZ report no conflicts of interest. At the outset of the work,
528 Niall Harrison was an employee of Ogilvy Health UK and William Gattrell was an employee
529 of Ipsen.

530

531 **Funding statement**

532 The open access fee for this article was provided by Oxford PharmaGenesis.

533

534 **Ethics statement**

535 Ethics approval was obtained from the Medical Sciences Interdivisional Research Ethics

536 Committee at the University of Oxford (reference number R81767/RE001)

537

538 **References**

539

540 1. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based
541 medicine: what it is and what it isn't. *BMJ*. 1996;312(7023):71-2. doi:
542 10.1136/bmj.312.7023.71. PubMed PMID: 8555924; PubMed Central PMCID:
543 PMC2349778.

- 544 2. Szajewska H. Evidence-based medicine and clinical research: both are needed, neither
545 is perfect. *Ann Nutr Metab.* 2018;72 Suppl 3:13-23. Epub 20180409. doi:
546 10.1159/000487375. PubMed PMID: 29631266.
- 547 3. Greenhalgh T. Will COVID-19 be evidence-based medicine's nemesis? *PLoS Med.*
548 2020;17(6):e1003266. Epub 20200630. doi: 10.1371/journal.pmed.1003266. PubMed PMID:
549 32603323; PubMed Central PMCID: PMCPCMC7326185.
- 550 4. Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al.
551 Consensus development methods, and their use in clinical guideline development. *Health*
552 *Technol Assess.* 1998;2(3):i-iv, 1-88. PubMed PMID: 9561895.
- 553 5. Kurvers RH, Herzog SM, Hertwig R, Krause J, Carney PA, Bogart A, et al. Boosting
554 medical diagnostics by pooling independent judgments. *Proc Natl Acad Sci U S A.*
555 2016;113(31):8777-82. Epub 20160718. doi: 10.1073/pnas.1601827113. PubMed PMID:
556 27432950; PubMed Central PMCID: PMCPCMC4978286.
- 557 6. Surowiecki J. *The wisdom of crowds.* New York, USA: Anchor; 2004.
- 558 7. Woolley AW, Chabris CF, Pentland A, Hashmi N, Malone TW. Evidence for a
559 collective intelligence factor in the performance of human groups. *Science.*
560 2010;330(6004):686-8. Epub 20100930. doi: 10.1126/science.1193147. PubMed PMID:
561 20929725.
- 562 8. van Zuuren EJ, Logullo P, Price A, Fedorowicz Z, Hughes EL, Gattrell WT. Existing
563 guidance on reporting of consensus methodology: a systematic review to inform ACCORD
564 guideline development. *BMJ Open.* 2022;12(9):e065154. Epub 20220908. doi:
565 10.1136/bmjopen-2022-065154. PubMed PMID: 36201247; PubMed Central PMCID:
566 PMCPCMC9462098.
- 567 9. Barnes C, Boutron I, Giraudeau B, Porcher R, Altman DG, Ravaud P. Impact of an
568 online writing aid tool for writing a randomized trial report: the COBWEB (Consort-based
569 WEB tool) randomized controlled trial. *BMC Med.* 2015;13:221. Epub 20150915. doi:
570 10.1186/s12916-015-0460-y. PubMed PMID: 26370288; PubMed Central PMCID:
571 PMCPCMC4570037.
- 572 10. Dechartres A, Trinquart L, Atal I, Moher D, Dickersin K, Boutron I, et al. Evolution
573 of poor reporting and inadequate methods over time in 20 920 randomised controlled trials
574 included in Cochrane reviews: research on research study. *BMJ.* 2017;357:j2490. Epub
575 20170608. doi: 10.1136/bmj.j2490. PubMed PMID: 28596181.
- 576 11. Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT
577 Statement impact the completeness of reporting of randomised controlled trials published in
578 medical journals? A Cochrane review. *Syst Rev.* 2012;1:60. Epub 20121129. doi:
579 10.1186/2046-4053-1-60. PubMed PMID: 23194585; PubMed Central PMCID:
580 PMCPCMC3564748.
- 581 12. Blazey P, Crossley KM, Ardern CL, van Middelkoop M, Scott A, Khan KM. It is
582 time for consensus on 'consensus statements'. *Br J Sports Med.* 2022;56(6):306-7. Epub
583 20210923. doi: 10.1136/bjsports-2021-104578. PubMed PMID: 34556467; PubMed Central
584 PMCID: PMCPCMC8899487.
- 585 13. Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al.
586 Defining consensus: a systematic review recommends methodologic criteria for reporting of
587 Delphi studies. *J Clin Epidemiol.* 2014;67(4):401-9. doi: 10.1016/j.jclinepi.2013.12.002.
588 PubMed PMID: 24581294.
- 589 14. Gupta UG CR. Theory and applications of the Delphi technique: a bibliography
590 (1975-1994). *Technol Forecast Social Change.* 1996;53(2):185-211.
- 591 15. Spranger J, Homberg A, Sonnberger M, Niederberger M. Reporting guidelines for
592 Delphi techniques in health sciences: a methodological review. *Z Evid Fortbild Qual*

- 593 Gesundhwes. 2022;172:1-11. Epub 20220617. doi: 10.1016/j.zefq.2022.04.025. PubMed
594 PMID: 35718726.
- 595 16. Junger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on Conducting and
596 REporting DELphi Studies (CREDES) in palliative care: recommendations based on a
597 methodological systematic review. *Palliat Med*. 2017;31(8):684-706. Epub 20170213. doi:
598 10.1177/0269216317690685. PubMed PMID: 28190381.
- 599 17. Brouwers MC, Kerkvliet K, Spithoff K, Consortium ANS. The AGREE Reporting
600 Checklist: a tool to improve reporting of clinical practice guidelines. *BMJ*. 2016;352:i1152.
601 Epub 20160308. doi: 10.1136/bmj.i1152. PubMed PMID: 26957104; PubMed Central
602 PMCID: PMC5118873.
- 603 18. Gattrell WT, Hungin AP, Price A, Winchester CC, Tovey D, Hughes EL, et al.
604 ACCORD guideline for reporting consensus-based methods in biomedical research and
605 clinical practice: a study protocol. *Res Integr Peer Rev*. 2022;7(1):3. Epub 20220607. doi:
606 10.1186/s41073-022-00122-0. PubMed PMID: 35672782; PubMed Central PMCID:
607 PMC9171734.
- 608 19. Woudenberg F. An evaluation of Delphi. *Technological Forecasting and Social
609 Change*. 1991;40(2):131-50.
- 610 20. Delbecq AL, van de Ven AH, Gustafson DH. *Group Techniques for Program
611 Planning: a guide to nominal group and Delphi processes*. Glenview, Illinois, USA: Scott,
612 Foresman and Company; 1975.
- 613 21. Fitch K, Bernstein S, Aguilar M, Burnand B, LaCalle J, Lazaro P, et al. The
614 RAND/UCLA appropriateness method user's manual 2001 [cited 2023 6 June]. Available
615 from: https://www.rand.org/pubs/monograph_reports/MR1269.html.
- 616 22. van Melick N, van Cingel RE, Brooijmans F, Neeter C, van Tienen T, Hullegie W, et
617 al. Evidence-based clinical practice update: practice guidelines for anterior cruciate ligament
618 rehabilitation based on a systematic review and multidisciplinary consensus. *Br J Sports Med*.
619 2016;50(24):1506-15. Epub 20160818. doi: 10.1136/bjsports-2015-095898. PubMed PMID:
620 27539507.
- 621 23. Open Science Framework. ACCORD registration with the Open Science Framework
622 2022 [cited 2023 6 June]. Available from: <https://osf.io/2rzm9>.
- 623 24. The EQUATOR Network. ACCORD registration at the EQUATOR Network 2021
624 [cited 2023 6 June]. Available from: <https://www.equator-network.org/library/reporting-guidelines-under-development/reporting-guidelines-under-development-for-other-study-designs/#ACCORD>.
- 625
626
- 627 25. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health
628 research reporting guidelines. *PLoS Med*. 2010;7(2):e1000217. Epub 20100216. doi:
629 10.1371/journal.pmed.1000217. PubMed PMID: 20169112; PubMed Central PMCID:
630 PMC2821895.
- 631 26. Schlüssel MM, Sharp MK, de Beyer JA, Kirtley S, Logullo P, Dhiman P, et al.
632 Reporting guidelines used varying methodology to develop recommendations. *J Clin
633 Epidemiol*. 2023. Epub 20230323. doi: 10.1016/j.jclinepi.2023.03.018. PubMed PMID:
634 36965598.
- 635 27. The EQUATOR Network. EQUATOR Network Newsletter October 2021 2021 [cited
636 2023 6 June]. Available from: <https://mailchi.mp/e54a81276f98/the-equator-network-newsletter-october-2021>.
- 637
638
- 639 28. Clavisi O, Bragge P, Tavender E, Turner T, Gruen RL. Effective stakeholder
640 participation in setting research priorities using a Global Evidence Mapping approach. *J Clin
641 Epidemiol*. 2013;66(5):496-502 e2. Epub 20120718. doi: 10.1016/j.jclinepi.2012.04.002.
641 PubMed PMID: 22819249.

- 642 29. Dijkstra HP, Mc Auliffe S, Ardern CL, Kemp JL, Mosler AB, Price A, et al.
643 Infographic. Oxford consensus on primary cam morphology and femoroacetabular
644 impingement syndrome-natural history of primary cam morphology to inform clinical
645 practice and research priorities on conditions affecting the young person's hip. *Br J Sports*
646 *Med.* 2023;57(6):382-4. Epub 20230117. doi: 10.1136/bjsports-2022-106094. PubMed
647 PMID: 36650034; PubMed Central PMCID: PMCPMC9985723.
- 648 30. Staniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S, et al. GRIPP2
649 reporting checklists: tools to improve reporting of patient and public involvement in research.
650 *BMJ.* 2017;358:j3453. Epub 20170802. doi: 10.1136/bmj.j3453. PubMed PMID: 28768629;
651 PubMed Central PMCID: PMCPMC5539518.
- 652 31. von der Gracht A. Consensus measurement in Delphi studies: review and implications
653 for future quality assurance. *Technol Forecast Social Change.* 2012;79(8):1525-36.
654

655

656 **Supporting information**

657 SI1 Steering Committee members

658 SI2 Steering Committee surveys

659 SI3 Information pack for Delphi panellists

660 SI4 Feedback documents provided to Delphi panellists

661 SI5 Summary of Delphi voting round

Flow chart of checklist items

